Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Embold: Elecoglipron in Obesity or Overweight With or Without Type 2 Diabetes Mellitus
jRCT2031260264Recruiting
- Sponsor
- AstraZeneca
- Start
- Jul 2026
- Modality
- Small Molecules
01
Overview
Randomised, double-blind trial of elecoglipron in obesity, Overweight, type 2 diabetes mellitus (T2DM) and 5 more (3 arms), sponsored by AstraZeneca. Primary endpoint: Percent body weight loss at Week 72. Started Jul 2026; status: recruiting.
02
Drugs
elecoglipron
03
Conditions
obesityOverweighttype 2 diabetes mellitus (T2DM)hypertension (HTN)prediabetes
Beyond the preview
Go deeper on jRCT2031260264.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031260264.